K-LOW Combo (Weight Loss Stack)
Research-focused weight management combo combining a GLP-1/GIP receptor agonist with AOD 9604 and Lipo-C for multi-pathway fat mobilisation and metabolic
Buy more, save more
Total Price
$285
For research & laboratory use only. Not for human consumption.
Half-Life
Varies by component
Administration Route
Subcutaneous injection
Effect Profile
Combined Efficacy
Synergistic Action
Protocol Coverage
Value
Mechanism of Action
Product FAQs
Stacks Well With
Tirzepatide
Dual GIP and GLP-1 receptor agonist. Among the most potent metabolic peptides studied to date, with clinical trials reporting up to 21% body weight reduction.
AOD 9604
Modified fragment of human growth hormone (hGH 177-191) with selective lipolytic activity and no reported effect on blood glucose or IGF-1. Studied for adipose
Lipo-C
Lipotropic injection combining methionine, inositol, and choline (MIC). Promotes hepatic fat metabolism, supports bile production, and is used in weight
Related Products
Tirzepatide
Dual GIP and GLP-1 receptor agonist. Among the most potent metabolic peptides studied to date, with clinical trials reporting up to 21% body weight reduction.
AOD 9604
Modified fragment of human growth hormone (hGH 177-191) with selective lipolytic activity and no reported effect on blood glucose or IGF-1. Studied for adipose
Lipo-C
Lipotropic injection combining methionine, inositol, and choline (MIC). Promotes hepatic fat metabolism, supports bile production, and is used in weight
Semaglutide
Long-acting GLP-1 receptor agonist. STEP-1 trial reported 14.9% average body weight reduction at 2.4mg weekly dose over 68 weeks.